ANTX

AN2 Therapeutics (ANTX)

AN2 Therapeutics Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:ANTX

1 2 3 4 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	05:12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/05/15	05:07	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/05/15	05:01	Edgar (US Regulatory)	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/05/15	05:01	Business Wire	AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/03/29	05:10	Business Wire	AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/02/14	07:11	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/02/12	21:01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/02/12	20:45	Business Wire	AN2 to Voluntarily Pause Enrollment in Phase 3 Part of Phase 2/3 Pivotal Clinical Trial Evaluating Epetraborole for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/31	06:10	Business Wire	AN2 Therapeutics to Present at Oppenheimer Healthcare Life Sciences Conference	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/19	08:19	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/18	07:03	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/13	07:08	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/12	09:59	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/05	08:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/05	08:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/03	06:45	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2024/01/03	06:36	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/11/17	08:57	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/11/10	06:15	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/11/10	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/11/10	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/11/10	06:05	Business Wire	AN2 Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business and Scientific Highlights	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/11/06	21:00	Business Wire	AN2 Therapeutics to Present at Upcoming Investor Conferences	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/10/18	20:00	Business Wire	AN2 Therapeutics Signs License Agreement with the University of Georgia Research Foundation to Develop Novel Boron-Based Therapy for Chagas Disease	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/10/11	13:01	Business Wire	AN2 Therapeutics to Present New Data for Epetraborole at IDWeek 2023	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/10/04	08:21	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/10/03	05:10	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/09/30	06:40	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/09/30	05:11	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:ANTX	AN2 Therapeutics Inc
2023/09/26	20:00	Business Wire	AN2 Therapeutics Signs Grant Agreement to Discover Novel, Boron Based Therapies for Tuberculosis and Malaria	NASDAQ:ANTX	AN2 Therapeutics Inc